

References

I-188

1. Pharmacy Drug Coverage Policy Manual. North Dakota Department of Health and Human Services. Medical Services Division. [Preferred Drug List \(PDL\) - North Dakota Medicaid](#)
2. Clinical Pharmacology Compendia. Tampa FL: Gold Standard, Inc. 2020. Vestronidase alfa.
3. MepseviiTM (vestronidase alfa-vjbk) for intravenous infusion [package insert]. Ultragenyx Pharmaceutical, Inc. Novato, CA. Revised 12/2019.
4. Montano A, Lock-Hock N, Steiner R, et al. Clinical course of sly syndrome (Mucopolysaccharidosis Type VII). J Med Genet. 2016;53(6):403-418.
5. Fox J, Volpe L, Bullaro J, et al. Treatment with investigational rhGUS enzyme replacement therapy in an advanced stage MPS VII patient. Mol Genet Metab. 2015;114(2):203-208.
6. Qi Y, McKeever K, Taylor J, et al. Pharmacokinetic and pharmacodynamic modeling to optimize the dose of vestronidase alfa, an enzyme replacement therapy for treatment of patients with mucopolysaccharidosis type VII: results from three trials. Clin Pharmacokinet 2019;58(5):673-83.
7. Harmatz P, Whitley CB, Wang RY, et al. A novel blind start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease. Mol Genet Metab. 2018;123(4):488–94.
8. MCG™ Care Guidelines, 22nd edition, 2018, Home Infusion Therapy, CMT: CMT-0009(SR).
9. Polinski JM, Kowal MK, Gagnon M, et al. Home infusion: safe clinically effective, patient preferred, and cost saving. Healthcare. 2016.
10. Morrison A, Oussoren E, Friedel T, et al. Pathway to diagnosis and burden of illness in mucopolysaccharidosis type VII—a European caregiver survey. Orphanet J Rare Dis. 2019;14 (1):254
11. McCafferty EH, Scott LJ. Vestronidase alfa: a review in mucopolysaccharidosis VII. BioDrugs. 2019;11;33(2):233-240.